The decline of pharmaceutical psychiatry and the increasing role of psychological medicine

Psychotherapy and Psychosomatics

Volumn 78, Issue 4, 2009, Pages 220-227

  Fava, Giovanni A ^a,b  

^a UNIVERSITY OF BOLOGNA   (Italy)

^b UNIVERSITY AT BUFFALO   (United States)

Author keywords

Antidepressive agents; Conflict of interest; Depressive disorder; Pharmaceutical psychiatry; Psychological medicine; Psychological well being; Psychosomatic medicine; Psychotherapy

Indexed keywords

ANTIDEPRESSANT AGENT; PSYCHOTROPIC AGENT;

BEHAVIOR; COGNITIVE THERAPY; CONFLICT OF INTEREST; DEPRESSION; DRUG INDUSTRY; DRUG LABELING; DRUG MARKETING; MEDICAL ETHICS; MEDICAL PRACTICE; MEDICAL RESEARCH; NEUROBIOLOGY; PRIORITY JOURNAL; PSYCHIATRIST; PSYCHIATRY; PSYCHOLOGIC ASSESSMENT; PSYCHOLOGICAL ASPECT; PSYCHOLOGICAL MEDICINE; PSYCHOSOMATICS; PSYCHOTHERAPY; REVIEW; SELF CARE; TREATMENT RESPONSE;

ANTIDEPRESSIVE AGENTS; CLINICAL TRIALS AS TOPIC; COMBINED MODALITY THERAPY; CONFLICT OF INTEREST; DEPRESSIVE DISORDER; DISCLOSURE; DRUG INDUSTRY; DRUG LABELING; FORECASTING; HUMANS; MENTAL DISORDERS; PATIENT CARE TEAM; PSYCHIATRY; PSYCHOPHARMACOLOGY; PSYCHOSOMATIC MEDICINE; PSYCHOTHERAPY; PUBLICATION BIAS; SELF CARE;

EID: 65449139541     PISSN: 00333190     EISSN: None     Source Type: Journal    
DOI: 10.1159/000214443     Document Type: Review

References (111)

1. Chalmers I: From optimism to disillusion about commitment to transparency in the medico-industrial complex. J R Soc Med 2006;99:337-341.
2. Smith R: Medical journals are an extension of the marketing arm of pharmaceutical companies. PLoS Med 2005;2:e138.
3. Jureidini JN, McHenry L, Mansfield PR: Clinical trials and drug promotion: selective reporting of study 329. Int J Risk Saf Med 2008;20:73-81.
4. Fava GA: Financial conflicts of interest in psychiatry. World Psychiatry 2007;6:19-24.
5. Maj M: Are we able to differentiate between true mental disorders and homeostatic reactions to adverse life events? Psychother Psychosom 2007;73:257-259.
6. Whitaker R: Anatomy of an epidemic: psychiatric drugs and the astonishing rise of mental illness in America. Eth Hum Psychol Psychiatry 2005;7:23-35.
7. Harris G, Carey B: Researchers fail to reveal full drug pay. New York Times, June 8, 2008.
8. Prince M, Patel V, Saxena S, Maj M, Maselko J, Phillips MR, Rahman A: No health without mental health. Lancet 2007;370:849-877.
9. Cosgrove L, Krimsky S, Vijaraghavan M, Schneider L: Financial ties between DSM-IV panel members and the pharmaceutical industry. Psychother Psychosom 2006;75:154-160.
10. Krimsky S: Journal policies on conflict of interest: if this is the therapy, what's the disease? Psychother Psychosom 2001;70:115-117.
11. Armstrong D: Medical journal editor to quit in wake of disclosure oversight. Wall Street Journal, August 25, 2006.
12. Perlis RH, Perlis CS, Wu Y, Hwang C, Josep M, Nierenberg AA: Industry sponsorship and financial conflict of interest in the reporting of clinical trials in psychiatry. Am J Psychiatry 2005;162:1957-1960.
13. Melander H, Ahlquist-Rastad J, Beermann B: Evidence b(i)ased medicine: selective reporting from studies sponsored by the pharmaceutical industry. BMJ 2003;326:1171-1175.
14. Montgomer y J H, Byerly M, Carmody T, Li B, Miller DR, Va rghese F, Holland R: Ananalysis of the effect of funding source in randomized clinical trials of second generation anti-psychotics for the treatment of schizophrenia. Control Clin Trials 2004;25:598-612.
15. Kelly RE, Cohen LJ, Semple RJ, Bialer P, Lan A, Bodenheimer A, Neudstadter E, Bareboim A, Galynker II: Relationship between drug company funding and outcomes of clinical psychiatric research. Psychol Med 2006;36:1647-1656.
16. Starcevic V: Opportunistic 'rediscovery' of mental disorders by the pharmaceutical, industr y. Psychother Psychosom 2002;71:305-310.
17. Carroll BJ: Neurobiologic dimensions of depression and mania; in Angst J (ed): The Origins of Depression. Berlin, Springer, 1983, pp 163-186.
18. Mojtabai R: Increase in antidepressant medication in the US adult population between 1990 and 2003. Psychother Psychosom 2008;77:83-92.
19. Wazana A: Physicians and the pharmaceutical industry. JAMA 2000;283:373-380.
20. Lurie P, Tran T, Wolfe SM, Goodman R: Violations of exhibiting and FDA rules at an American Psychiatric Association annual meeting. J Public Health Policy 2005;26:389-399.
21. Carroll BJ: Antipsychotic drugs for depression? http://hcrenewal. blogspot.com/2008/01/antipsychotic-drugs-for-depression.html.
22. Turner EH, Matthews AM, Linardatos E, Tell RA, Rosenthal R: Selective publication of antidepressant trials and its influence on apparent efficacy. N Engl J Med 2008;358:252-260.
23. Kirsch I, Deacon BJ, Huedo-Medina TB, Scoboria A, Moore TJ, Johnson BT: Initial severity and antidepressant benefits: a meta-analysis of data submitted to the Food and Drug Administration. PLoS Med 2008;5: e45.
24. Gibbons RD, Davis JM: The price of beer and the salaries of priests: analysis and display of longitudinal psychiatric data. Arch Gen Psychiatry 1984;41:1183-1184.
25. Gibbons RD, Brown CH, Hur K, Marcus SM, Bhaumik DK, Mann JJ: Relationship between antidepressants and suicide attempts: an analysis of the Veterans Health Administration data sets. Am J Psychiatry 2007;164:1044-1049.
26. Leckman JF, King RA: A development perspective on the controversy surrounding the use of SSRIs to treat pediatric depression. Am J Psychiatry 2007;164:1304-1306.
27. Jureidini J: The black box warning: decreased prescriptions and increased youth suicide? Am J Psychiatry 2007;164:1907.
28. Olfson M, Shaffer D: SSRI prescriptions and the rate of suicide. Am J Psychiatry 2007;164:1907-1908.
29. Wohlfarth T, Boer F, den Brink WV: Withdrawal of attention rather than pharmacological treatment affects suicide rates in depressed children and adolescents. Am J Psychiatry 2007;164:1908.
30. Simon G: Antidepressants and suicide: treatment is probably too sporadic to affect over-all suicide rates. BMJ 2008;336:515-516.
31. Wheeler BW, Gunnell D, Metcalfe C, Stephens P, Martin RM: The population impact on incidence of suicide and non-fatal self harm of regulatory action against the use of selective serotonin reuptake inhibitors in under 18s in the United Kingdom: ecological study. BMJ 2008;336:542-545.
32. Biddle L, Brock A, Brookes TS, Gunnell D: Suicide rates in young men in England and Wales in the 21st century: time trend study. BMJ 2008;336:539-542.
33. Fava GA: Can long-term treatment with antidepressant drugs worsen the course of depression? J Clin Psychiatry 2003;64:123-132.
34. Chouinard G, Chouinard VA: Atypical anti-psychotics. Psychother Psychosom 2008;77:69-77.
35. Lewontin RC: Biology as Ideology. New York, Harper and Collins, 1991.
36. Healy D: One flew over the conflict of interest nest. World Psychiatry 2007;6:26-27.
37. Lipowski ZJ: Psychiatry: mindless or brainless, both or neither? Can J Psychiatry 1989;34:249-254.
38. Kendler KS: Toward a philosophical structure for psychiatry. Am J Psychiatry 2005;162:433-440.
39. Kendler KS: 'A gene for.': the nature of gene action in psychiatric disorders. Am J Psychiatry 2005;162:1243-1252.
40. Fava GA: The intellectual crisis of psychiatric research. Psychother Psychosom 2006;75:202-208.
41. Engel GL: Clinical observation: the neglected basic method of medicine. JAMA 1965;192:157-160.
42. Klein DF: The loss of serendipity in psychopharmacology. JAMA 2008;299:1063-1065.
43. Moses H, Dorsey ER, Matheson DHM, Thier SO: Financial anatomy of biomedical research. JAMA 2005;294:1333-1342.
44. Engel GL: Physician-scientists and scientific physicians. Am J Med 1987;82:107-111.
45. Ahrens EH: The Crisis in Clinical Research. New York, Oxford University Press, 1992.
46. Bell J: Resuscitating clinical research in the United Kingdom. BMJ 2003;327:1041-1043.
47. Remuzzi G, Schieppati A, Boissel JP, Horton R: Independent clinical research in Europe. Lancet 2004;364:1723-1726.
48. Feinstein AR: The intellectual crisis in clinical science. Persp Biol Med 1987;30:215-230.
49. Tyrer P: Clinical use of monoamine oxidase inhibitors; in Paykel ES, Coppen A (eds): Psychopharmacology of Affective Disorders. Oxford, Oxford University Press, 1979, pp 159-178.
50. Nierenberg AA, Smoller J, Eidelman P, Wa YP, Tilley CA: Critical thinking about adverse drug effects: lessons for the psychology of risk and medical decision-making for clinical psychopharmacology. Psychother Psychosom 2008;77:201-208.
51. Healy D: Irrational healers? Psychother Psychosom 2008;77:198-200.
52. Gliedman CH, Nash EH, Huber SD, Stone AR, Frank JD: Reduction of symptoms by pharmacologically inert substances and by short-term psychotherapy. AMA Arch Neurol Psychiatry 1958;79:345-351.
53. Downing RW, Rickels K: Nonspecific factors and their interaction with psychological treatment in pharmacotherapy; in Lipton MA, Di Mascio A, Killam KF (eds): Psychopharmacology: A Generation of Progress. New York, Raven Press, 1978, pp 1419-1427.
54. Fava GA, Sonino N: The clinical domains of psychosomatic medicine. J Clin Psychiatry 2005;66:849-858.
55. Walach H, Bosch H, Lewith G, Naumann J, Schwarzer B, Falk S, Kohls N, Haraldsson E, Wiesdanger H, Nordmann A, Tomasson H, Rescott P, Bucher HC: Effectiveness of distant healing for patients with chronic fatigue syndrome. Psychother Psychosom 2008;77:158-166.
56. Uhlenhuth EN, Rickels K, Fisher S, Park LC, Lipman RS, Mock J: Drug, doctor's verbal attitude and clinic setting in the symptomatic response to pharmacotherapy. Psychopharmacologia 1966;9:392-418.
57. Rush AJ, Trivedi MH, Wisniewski SR, Nierenberg AA, Stewart JW, Warden D, Niederebe G, Thase ME, Lavori PW, Lebowitz BD, McGrath PJ, Rosenbaum JF, Sackheim HA, Kupfer DJ, Luther J, Fava M: Acute and long-term outcomes in depressed out-patients requiring one or several treatment steps. Am J Psychiatry 2006;163:1905-1917.
58. Nelson JC: The STAR* D Study. Am J Psychiatry 2006;163:1864-1866.
59. Fava GA, Tomba E, Grandi S: The road to recovery from depression. Psychother Psychosom 2007;76:260-265.
60. Simon GE, Von Korff M, Rutter CM, Peterson DA: Treatment process and outcomes for managed care patients receiving new antide-pressant prescriptions for psychiatrists and primary cure physicians. Arch Gen Psychiatry 2001;58:395-401.
61. Lin EHB, Simon GE, Katon WJ, Russo JE, Von Korff M, Bush TM, Ludman EJ, Walker EA: Can enhanced acute-phase treatment of depression improve long-term outcomes? Am J Psychiatr y 1999;156:643-645.
62. Thompson C, Kinmonth AL, Stevens L, Peveler RC, Stevens A, Ostler KJ, Pickering RM, Baker NG, Henson A, Preece J, Cooper D, Campbell MJ: Effects of a clinical practice guideline and practice-based education on detection and outcome of depression in primary care. Lancet 2000;355:185-191.
63. Katon WJ, Rutter C, Ludman EJ, Von Korff M, Lin E, Simon G, Bush T, Walker E, Unutzer J: A randomized trial of relapse prevention of depression in primary care. Arch Gen Psychiatry 2001;58:241-247.
64. Mokdad AH, Merks JS, Stroup DF, Geberding JL: Actual causes of death in the United States, 2000. JAMA 2004;291:1238-1245.
65. Narayan KMV, Kanaya AM, Gregg EW: Lifestyle interventions for the prevention of type 2diabetes mellitus. Treat Endocrinol 2003;2:315-320.
66. Fava GA, Ruini C, Rafanelli C: Sequential treatment of mood and anxiety disorders. J Clin Psychiatry 2005;66:1392-1400.
67. Fava GA, Rafanelli C, Grandi S, Canestrari R, Morphy MA: Six year outcome for cognitive behavioural treatment of residual symptoms in major depression. Am J Psychiatry 1998;155:1443-1445.
68. Fava GA, Ruini C, Rafanelli C, Finos L, Conti S, Grandi S: Six year outcome of cognitive behavior therapy for prevention of recurrent depression. Am J Psychiatry 2004;161:1872-1876.
69. Paykel ES, Scott J, Cornwall PL, Abbott R, Crane C, Pope M, Johnson AL: Duration of relapse prevention after cognitive therapy in residual depression. Psychol Med 2005;35:59-68.
70. Fava GA, Ruini C, Belaise C: The concept of recovery in major depression. Psychol Med 2007;37:307-317.
71. Marks IM: The maturing of therapy. Br J Psychiatry 2002;180:200-204.
72. Layard R: The case for psychological treatment centres. BMJ 2006;332:1030-1032.
73. Fava GA, Park SK, Dubovsky SL: The mental health clinic: a new model. World Psychiatry 2008;7:177-181.
74. Shepherd M: Psychiatric journals and the evolution of psychological medicine. Psychol Med 1992;22:15-25.
75. Lloyd GG, Mayou RA: Liaison psychiatry or psychological medicine? Br J Psychiatry 2003;183:5-7.
76. Kroenke K: Psychological medicine: integrating psychological care into general medical practice. BMJ 2002;324:1536-1537.
77. Gask L: ABC of psychological medicine: the consultation. BMJ 2002;324:1567-1569.
78. Price L, Leaver L: ABC of psychological medicine: beginning treatment. BMJ 2002;325:33-35.
79. Mayou R, Farmer A: ABC of psychological medicine: functional somatic symptoms and syndromes. BMJ 2002;325:265-268.
80. Ryle JA: The Hippocratic ideal. Lancet 1935;ii:1263-1268.
81. Ryle JA: Changing Disciplines: Lectures on the History, Method and Motives of Social Pathology. London, Oxford University Press, 1948.
82. Holman HR: The 'excellence' deception in medicine. Hosp Pract 1976;11:11-21.
83. Engel GL: The need for a new medical model: a challenge for biomedicine. Science 1977;196:129-136.
84. Fava GA, Sonino N: The biopsychosocial model thirty years later. Psychother Psychosom 2008;77:1-2.
85. Romano J: Requiem or reveille: the clinician's choice. J Med Educ 1963;38:584-590.
86. Engel GL: A unified concept of health and disease. Persp Biol Med 1960;3:459-484.
87. WHO: World Health Organization Constitution. Geneva, WHO, 1948, p 28.
88. Ryff CD, Singer B: Psychological well-being. Psychother Psychosom 1996;65:14-23.
89. Kellner R: A symptom questionnaire. J Clin Psychiatry 1987;48:269-274.
90. Wittchen HU: Continued needs for epidemiological studies of mental disorders in the community. Psychother Psychosom 2004;73:197-206.
91. Fava GA, Ruini C: Development and characteristics of a well-being enhancing psychotherapeutic strategy. J Behav Ther Exp Psychiatry 2003;34:45-63.
92. Forstmeier S, Rueddel H: Improving volitional competence is crucial for the efficacy of psychosomatic therapy. Psychother Psychosom 2007;70:89-96.
93. Maj M: The aftermath of the concept of psychiatric comorbidity. Psychother Psychosom 2005;74:67-68.
94. Stiefel F, Zdrojewski C, Bel Hadj F, Boffa D, Dorogi Y, So A, Ruiz J, de Jonge P: Effects of a multifaceted psychiatric intervention targeted for the complex medically ill. Psychother Psychosom 2008;77:247-256.
95. Starfield B: Threads and yarns: weaving the tapestry of comorbidity. Ann Fam Med 2006;4:101-103.
96. Ferrari S, Galeazzi GM, Mackinnon A, Rigatelli M: Frequent attenders in primary care. Psychot her Psychosom 2008;77:306-314.
97. Dubovsky SL: Treatment of bipolar depression. Psychiatry Clin North Am 2005;28:349-370.
98. Ghaemi SN, Baldessarini RJ: The manic-depressive spectrum and mood stabilization: Kraepelin's ghost. Psychother Psychosom 2007;76:65-69.
99. Benazzi F: Is there continuity between bipolar and depressive disorders? Psychother Psychosom 2007;76:70-76.
100. Fava GA, Rafanelli C, Tossani E, Grandi S: Agoraphobia is a disease: a tribute to Sir Martin Roth. Psychother Psychosom 2008;77:133-138.
101. Hetrick SE, Parker AG, Hickie IB, Purall R, Yung AR, McGorry PD: Early identification and intervention in depressive disorders: towards a clinical staging model. Psychother Psychosom 2008;77:263-270.
102. Moncrieff J, Cohen D: Rethinking models of psychotropic drug action. Psychother Psychosom 2005;74:145-153.
103. Fava M, Evins AE, Dorer DJ, Schoenfeld DA: The problem of the placebo response in clinical trials for psychiatric disorders. Psychother Psychosom 2003;72:115-127.
104. Moras K: The value of neuroscience strategies to accelerate progress in psychological treatment research. Can J Psychiatry 2006;51:810-822.
105. Frank JD, Frank JB: Persuasion and Healing, ed 3. Baltimore, Johns Hopkins University Press, 1991.
106. de Figueiredo JM: Demoralization and psychotherapy. Psychother Psychosom 2007;76:129-133.
107. Barlow JH, Ellard DR, Hainsworth JM, Jones FR, Fisher A: A review of self-management interventions for panic disorders, phobias and obsessive compulsive disorders. Acta Psychiatr Scand 2005;111:272-285.
108. Baer L, Greist J, Marks IM: Computer-aided cognitive behaviour therapy. Psychother Psychosom 2007;70:193-195.
109. Tumur I, Kaltenthaler E, Ferriter M, Beverley C, Parry G: Computerised cognitive behaviour therapy for obsessive-compulsive disorder. Psychother Psychosom 2007;76:196-202.
110. Petersdorf RG: A matter of integrity. Acad Med 1989;64:119-123.
111. Tinetti ME, Fried T: The end of the disease era. Am J Med 2004;116:179-185.